QR Code

Dual Targeting of Mutant p53 and SNRPD2 via Engineered Exosomes Modulates Alternative Splicing to Suppress Ovarian Cancer

ABSTRACT Mutation of the tumor suppressor gene TP53 promotes ovarian cancer progression and therapeutic resistance. Whether mutant p53 (mtp53) regulates alternative splicing and how this regulation can be exploited for cancer therapy remain unclear. Here, small nuclear ribonucleoprotein D2 polypepti...

Whakaahuatanga katoa

I tiakina i:
Ngā kaituhi matua: Wei Zhao, Qian Hao, Yu Gan, Jing Tong, Xiaodan Chen, Shuran Tan, Ruiwen Ruan, Yingdan Huang, Mingming Cao, Jun Deng, Tao Han, Getao Shi, Bo Gao, Yu Zhang, Xiang Zhou
Hōputu: Artigo
Reo:Inglês
I whakaputaina: Wiley 2026-03-01
Rangatū:Advanced Science
Ngā marau:
alternative splicing
engineered exosomes
p53
SNRPD2
targeted therapy
Urunga tuihono:https://doi.org/10.1002/advs.202513369
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite